ICG-Cisplatin Nanoprobe (NIR-II NanoM)

Phase 1Small molecule

ICG-Cisplatin Nanoprobe (NIR-II NanoM) is one of 2 small molecule programs targeting Fluorescence. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

FluorescenceRecruiting

FluorescencePhase 1

Recruiting

Competition

Competitive Landscape

6 competitors in Fluorescence

#DrugCompanyPhaseTrials

Humira

Novartis

Phase 2

1 2

ICG-Cisplatin Nanoprobe (NIR-II NanoM)

WWest China Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Fluorescence

NCT07295262

Clinical

Trials by Indication[1]

Fluorescence1 trial

NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC

Recruiting·WWest China Hospital·Phase 1·NCT07295262·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ICG-Cisplatin Nanoprobe (NIR-II NanoM). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ICG-Cisplatin Nanoprobe (NIR-II NanoM) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ICG-Cisplatin Nanoprobe (NIR-II NanoM). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — West China Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: WWest China Hospital

ICG-Cisplatin Nanoprobe (NIR-II NanoM)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Fluorescence1 trial

References

Drug Info

Quick Facts

Related News